More than 6,000 patients in Greece are currently receiving free medication, a program that has been running for over seven years, according to a recent video release. The initiative, initially focused on providing access to pharmaceuticals for vulnerable populations, has expanded in recent months to include treatments for conditions like obesity and kidney dysfunction.
The expansion comes as part of a broader national program aimed at preventing and addressing cardiovascular risk factors. A joint ministerial decision, signed on December 10, 2025, formalized the inclusion of free medication for obesity, funded through the Recovery and Resilience Facility. This program targets early intervention for significant risk factors contributing to heart disease.
While the concept of “free medication” exists within the Greek healthcare system, it does not necessarily equate to zero cost for all patients, regardless of the chosen medication. Specific groups, including low-income pensioners who meet the same income criteria as former recipients of the Social Solidarity Income (EKA), individuals with certain medical conditions, and uninsured or otherwise vulnerable social groups, are eligible for exemptions from co-payments.
The new programs for obesity and kidney dysfunction are intended to complement existing provisions. Generally, insured patients executing a prescription at a private pharmacy are required to pay a standard co-payment of 25% of the drug’s official price. However, exemptions exist, and eligibility criteria are determined on a case-by-case basis.
The Ministry of Health announced the launch of the free medication program for obesity on December 10, 2025, stating that it is part of the “Prophylaxis” national program. The initiative is expected to benefit thousands of patients struggling with obesity.
Further details regarding the specific criteria for accessing free medication for obesity and kidney dysfunction, and the process for enrollment, have not yet been publicly released beyond the initial ministerial announcements. The Ministry of Health has not responded to requests for clarification on the implementation timeline or the specific medications covered under the new programs.
